These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 21208651)

  • 1. Dasatinib (BMS-35482) has synergistic activity with paclitaxel and carboplatin in ovarian cancer cells.
    Teoh D; Ayeni TA; Rubatt JM; Adams DJ; Grace L; Starr MD; Barry WT; Berchuck A; Murphy SK; Secord AA
    Gynecol Oncol; 2011 Apr; 121(1):187-92. PubMed ID: 21208651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of the multikinase inhibitor dasatinib against ovarian cancer cells.
    Konecny GE; Glas R; Dering J; Manivong K; Qi J; Finn RS; Yang GR; Hong KL; Ginther C; Winterhoff B; Gao G; Brugge J; Slamon DJ
    Br J Cancer; 2009 Nov; 101(10):1699-708. PubMed ID: 19861960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dasatinib (BMS-35482) interacts synergistically with docetaxel, gemcitabine, topotecan, and doxorubicin in ovarian cancer cells with high SRC pathway activation and protein expression.
    Secord AA; Teoh D; Jia J; Nixon AB; Grace L; Adams DJ; Murphy SK
    Int J Gynecol Cancer; 2014 Feb; 24(2):218-25. PubMed ID: 24407585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells.
    Le XF; Mao W; He G; Claret FX; Xia W; Ahmed AA; Hung MC; Siddik ZH; Bast RC
    J Natl Cancer Inst; 2011 Sep; 103(18):1403-22. PubMed ID: 21813412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dasatinib enhances antitumor activity of paclitaxel in ovarian cancer through Src signaling.
    Xiao J; Xu M; Hou T; Huang Y; Yang C; Li J
    Mol Med Rep; 2015 Sep; 12(3):3249-3256. PubMed ID: 25975261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I trial of dasatinib, an SRC-family kinase inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer.
    Secord AA; Teoh DK; Barry WT; Yu M; Broadwater G; Havrilesky LJ; Lee PS; Berchuck A; Lancaster J; Wenham RM
    Clin Cancer Res; 2012 Oct; 18(19):5489-98. PubMed ID: 22837181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic antitumor effects of dasatinib and oxaliplatin in gastric cancer cells.
    Shi M; Lou B; Ji J; Shi H; Zhou C; Yu Y; Liu B; Zhu Z; Zhang J
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):35-44. PubMed ID: 23712327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dasatinib + Gefitinib, a non platinum-based combination with enhanced growth inhibitory, anti-migratory and anti-invasive potency against human ovarian cancer cells.
    Thibault B; Jean-Claude B
    J Ovarian Res; 2017 Apr; 10(1):31. PubMed ID: 28446239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth.
    Marchion DC; Bicaku E; Xiong Y; Bou Zgheib N; Al Sawah E; Stickles XB; Judson PL; Lopez AS; Cubitt CL; Gonzalez-Bosquet J; Wenham RM; Apte SM; Berglund A; Lancaster JM
    Oncol Rep; 2013 May; 29(5):2011-8. PubMed ID: 23467907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting SRC in mucinous ovarian carcinoma.
    Matsuo K; Nishimura M; Bottsford-Miller JN; Huang J; Komurov K; Armaiz-Pena GN; Shahzad MM; Stone RL; Roh JW; Sanguino AM; Lu C; Im DD; Rosenshien NB; Sakakibara A; Nagano T; Yamasaki M; Enomoto T; Kimura T; Ram PT; Schmeler KM; Gallick GE; Wong KK; Frumovitz M; Sood AK
    Clin Cancer Res; 2011 Aug; 17(16):5367-78. PubMed ID: 21737505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nilotinib in combination with carboplatin and paclitaxel is a candidate for ovarian cancer treatment.
    Weigel MT; Rath K; Alkatout I; Wenners AS; Schem C; Maass N; Jonat W; Mundhenke C
    Oncology; 2014; 87(4):232-45. PubMed ID: 25116401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
    Witham J; Valenti MR; De-Haven-Brandon AK; Vidot S; Eccles SA; Kaye SB; Richardson A
    Clin Cancer Res; 2007 Dec; 13(23):7191-8. PubMed ID: 18056200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic activity of the SRC family kinase inhibitor dasatinib and oxaliplatin in colon carcinoma cells is mediated by oxidative stress.
    Kopetz S; Lesslie DP; Dallas NA; Park SI; Johnson M; Parikh NU; Kim MP; Abbruzzese JL; Ellis LM; Chandra J; Gallick GE
    Cancer Res; 2009 May; 69(9):3842-9. PubMed ID: 19383922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Src kinase inhibition induced by dasatinib in non-small cell lung cancer cell lines treated with cisplatin.
    Ceppi P; Papotti M; Monica V; Lo Iacono M; Saviozzi S; Pautasso M; Novello S; Mussino S; Bracco E; Volante M; Scagliotti GV
    Mol Cancer Ther; 2009 Nov; 8(11):3066-74. PubMed ID: 19861409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells.
    Pichot CS; Hartig SM; Xia L; Arvanitis C; Monisvais D; Lee FY; Frost JA; Corey SJ
    Br J Cancer; 2009 Jul; 101(1):38-47. PubMed ID: 19513066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic drug sensitivity testing reveals synergistic growth inhibition by dasatinib or mTOR inhibitors with paclitaxel in ovarian granulosa cell tumor cells.
    Haltia UM; Andersson N; Yadav B; Färkkilä A; Kulesskiy E; Kankainen M; Tang J; Bützow R; Riska A; Leminen A; Heikinheimo M; Kallioniemi O; Unkila-Kallio L; Wennerberg K; Aittokallio T; Anttonen M
    Gynecol Oncol; 2017 Mar; 144(3):621-630. PubMed ID: 28104295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Navitoclax augments the activity of carboplatin and paclitaxel combinations in ovarian cancer cells.
    Stamelos VA; Robinson E; Redman CW; Richardson A
    Gynecol Oncol; 2013 Feb; 128(2):377-82. PubMed ID: 23168176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dasatinib synergizes with both cytotoxic and signal transduction inhibitors in heterogeneous breast cancer cell lines--lessons for design of combination targeted therapy.
    Park BJ; Whichard ZL; Corey SJ
    Cancer Lett; 2012 Jul; 320(1):104-10. PubMed ID: 22306341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.
    Dunn EF; Iida M; Myers RA; Campbell DA; Hintz KA; Armstrong EA; Li C; Wheeler DL
    Oncogene; 2011 Feb; 30(5):561-74. PubMed ID: 20956938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapamycin by itself and additively in combination with carboplatin inhibits the growth of ovarian cancer cells.
    Schlosshauer PW; Li W; Lin KT; Chan JL; Wang LH
    Gynecol Oncol; 2009 Sep; 114(3):516-22. PubMed ID: 19576622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.